Search | IOVS | ARVO Journals

Showing 1 – 20 of 24

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Rishi P Singh; Robin Hamilton; Jeffrey S Heier; Carl Regillo; Mark C Gillies; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1158. doi:

ARVO Annual Meeting Abstract June 2020

Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration

Raj Maturi; Glenn J Jaffe; Justis P Ehlers; Peter K Kaiser; David S Boyer; Jeffrey S Heier; Julia A Kornfield; Baruch D Kuppermann; Hugo Quiroz-Mercado; Janine Aubel; Lisa Karageozian; Vicken H Karageozian; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):1944. doi:

ARVO Annual Meeting Abstract June 2020

Analysis of choriocapillaris flow impairment in intermediate age-related macular degeneration as a predictor of progression to exudative choroidal neovascularization

Luísa Salles de Moura Mendonca; Jeffrey S Heier; David S Boyer; David M Brown; Sumit P Shah; A. Yasin Alibhai; Namrata Saroj; Sabin Dang; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4092. doi:

ARVO Annual Meeting Abstract July 2019

Detection of choroidal neovascular membranes using OCT Angiography: Learnings from the PROCON Study

Sabin Dang; Nadia K Waheed; David S Boyer; David M Brown; Sumit Shah; Jeffrey S. Heier

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):3482. doi:

ARVO Annual Meeting Abstract July 2019

Sustained neuroprotective effect of novel Aβ aggregation modulator GAL-101 shown in dry AMD and glaucoma models with transient peak concentrations using eye drops

Hermann Russ; Christopher Parsons; Yaniv Barkana; Andrew L. Pearlman; Jeffrey S. Heier; Leonard A Levin; Robert N Weinreb; Jeffrey M Liebmann

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5393. doi:

ARVO Annual Meeting Abstract July 2019

Treatment and Management of Neovascular AMD: Impact on Patients

Vincent W Li; Isaac R. Gabriel; Madeleine M Li; Andrew N Antoszyk; Carl W Baker; Pravin U Dugel; Roger A. Goldberg; Jeffrey S. Heier; Allen C Ho; John S Pollack; Charles Clifton Wykoff; Demetrios Vavvas; William W Li

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):136. doi:

ARVO Annual Meeting Abstract July 2018

Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study

Roger A Goldberg; Jeffrey S. Heier

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):782. doi:

ARVO Annual Meeting Abstract July 2018

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

Hugo Quiroz-Mercado; David S Boyer; Peter A Campochiaro; Jeffrey S. Heier; Peter K Kaiser; Julie Kornfield; Baruch D Kuppermann; Vicken H Karageozian; Hampar L Karageozian; Lisa Karageozian; John Y Park; Melvin Sarayba

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1960. doi:

ARVO Annual Meeting Abstract July 2018

First-in human study of SF0166 Topical Ophthalmic Solution in patients with diabetic macular edema

D. Edwards; David S Boyer; Peter K Kaiser; Jeffrey S. Heier; Ben Askew

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1961. doi:

ARVO Annual Meeting Abstract July 2018

Incidence of Vascularized Drusen in Non-Exudative Age-related Macular Degeneration using Spectral Domain Optical Coherence Tomography (OCT) Angiography

Chris Or; Jeffrey S. Heier; Namrata Saroj; A. Yasin Alibhai; Nadia K Waheed

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3229. doi:

ARVO Annual Meeting Abstract July 2018

Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs)

Dante Joseph Pieramici; Frank Holz; Jeffrey S. Heier; Srinivas R. Sadda; Brandon G Busbee; Emily Y. Chew; Paul Mitchell; Adnan Tufail; Christopher Brittain; Daniela Ferrara; Sarah Gray; Lee Honigberg; Jillian Martin; Barbara Tong; Jason Ehrlich; Neil M Bressler

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4948. doi:

ARVO Annual Meeting Abstract September 2016

Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Clinical Study Evaluating Luminate ® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion

Baruch D Kuppermann; David S Boyer; Peter K Kaiser; Jeffrey S Heier; Peter A Campochiaro; Hugo Quiroz-Mercado; Julia Kornfield; Lisa Karageozian; Mohamed A Genead; Hampar L Karageozian; Vicken H Karageozian

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12) doi:

ARVO Annual Meeting Abstract September 2016

ORBIT: A phase IV clinical study - lessons learned from patient selection criteria for ocriplasmin intravitreal injection

Brian C Joondeph; Jay S Duker; David S Boyer; Jeffrey S Heier; Peter K Kaiser; Mathew W MacCumber; Dante Joseph Pieramici

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):4063. doi:

ARVO Annual Meeting Abstract June 2015

Six-Month Results From the ORBIT Study: Ocriplasmin Research to Better Inform Treatment of Symptomatic Vitreomacular Adhesion

Jay S Duker; David S Boyer; Jeffrey S Heier; Peter K Kaiser; Mathew W MacCumber; Dante Joseph Pieramici

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):1203. doi:

ARVO Annual Meeting Abstract June 2015

Clinical Proof-of-Concept Study of Oral Synthetic cis -Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

David A Saperstein; Dante Joseph Pieramici; Kenneth N Sall; Jeffrey S Heier; David M Brown; David G Birch; Cecelia R Sanchez; Todd Klesert; Claire S Barnes; Ronald A Schuchard; RET IDA 02 Study Group

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):3791. doi:

ARVO Annual Meeting Abstract April 2014

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

Mitchell G Brigell; Peter A Campochiaro; Raafay Sophie; Michael Tolentino; Daniel Miller; David Browning; David S Boyer; Jeffrey S Heier; Kevin Peters

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1757. doi:

ARVO Annual Meeting Abstract March 2012

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

David M. Brown; Julia A. Haller; David S. Boyer; Jeffrey S. Heier; W. L. Clark; Alyson J. Berliner; Robert Vitti; Oliver Zeitz; Rupert Sandbrink

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):936. doi:

ARVO Annual Meeting Abstract March 2012

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Daniel B. Roth; Jeffrey S. Heier; Desmond Thompson; Yuhwen Soo; Robert Vitti; Namrata Saroj; Alyson J. Berliner; Georg Groeztbach; Olaf Sowade; Oliver Zeitz

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2042. doi:

ARVO Annual Meeting Abstract April 2011

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Manjula Patel; Brian B. Berger; Jeffrey S. Heier; David M. Brown; Peter A. Campochiaro; Michael T. Stumpp

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):582. doi:

ARVO Annual Meeting Abstract April 2011

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

Baruch D. Kuppermann; Julia A. Haller; Francesco Bandello; Rubens Belfort, Jr.; Anat Loewenstein; Mark Gillies,; Jeffrey S. Heier; Jenny Jiao; Xiao-Yan Li; Scott M. Whitcup

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3966. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Disease Activity Assessments with Brolucizumab vs Aflibercept in Patients with nAMD in HAWK and HARRIER

Safety and Efficacy of Risuteganib in Intermediate Non-exudative Age-Related Macular Degeneration

Analysis of choriocapillaris flow impairment in intermediate age-related macular degeneration as a predictor of progression to exudative choroidal neovascularization

Detection of choroidal neovascular membranes using OCT Angiography: Learnings from the PROCON Study

Sustained neuroprotective effect of novel Aβ aggregation modulator GAL-101 shown in dry AMD and glaucoma models with transient peak concentrations using eye drops

Treatment and Management of Neovascular AMD: Impact on Patients

Short-Term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP CSC) – A Randomized, Placebo-Controlled Study

Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema

First-in human study of SF0166 Topical Ophthalmic Solution in patients with diabetic macular edema

Incidence of Vascularized Drusen in Non-Exudative Age-related Macular Degeneration using Spectral Domain Optical Coherence Tomography (OCT) Angiography

Lampalizumab for geographic atrophy (GA) in age-related macular degeneration (AMD): pooled results of the Chroma and Spectri phase 3 randomized clinical trials (RCTs)

Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Clinical Study Evaluating Luminate ® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion

ORBIT: A phase IV clinical study - lessons learned from patient selection criteria for ocriplasmin intravitreal injection

Six-Month Results From the ORBIT Study: Ocriplasmin Research to Better Inform Treatment of Symptomatic Vitreomacular Adhesion

Clinical Proof-of-Concept Study of Oral Synthetic cis -Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision

A Phase 1b/2a Open-Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28-Day Repeat Subcutaneous Doses of AKB-9778 in Subjects with Diabetic Macular Edema

Intravitreal Aflibercept Injection in Central Retinal Vein Occlusion: 1-year Results of the Phase 3 COPERNICUS Study

Cumulative Incidence of Visual Acuity Change in the VIEW 1 and VIEW 2 Studies of Patients with Neovascular Age-related Macular Degeneration

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Efficacy of Dexamethasone Intravitreal Implant for Best Corrected Visual Acuity in Patients With Retinal Vein Occlusion After 7 Days

To View More...

You must be signed into an individual account to use this feature.